Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sorafenib monotherapy Variant #04 | — | R 37 339 | 28d | — | — | — | — | 1 |
Imatinib monotherapy Variant #17 | — | R 27 014 | 30d | ~20.0 mo | ~53.0 mo | ~21 | ~R 567 284 PFS proxy · indirect | 8 |
Pazopanib monotherapy Variant #01 | — | R 22 754 | 28d | ~4.3 mo | — | ~5 | ~R 113 768 PFS proxy · indirect | 3 |
Pegylated liposomal doxorubicin monotherapy Variant #01 | — | R 15 300 | 28d | ~4.2 mo | ~13.5 mo | ~5 | ~R 76 500 PFS proxy · indirect | 24 |
Methotrexate and Vinblastine Variant #01 | — | R 493 | 14d | — | — | — | — | — |
Nirogacestat monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | 1 |
Placebo Partial | — | — | — | — | — | — | — | 2 |
7 of 7 regimens shown